Search This Blog

Wednesday, July 22, 2026

Summit combo shows OS hazard ratio 0.76 in Phase III NSCLC trial, data submitted to FDA

 

Summit Therapeutics' ivonescimab plus chemo shows OS hazard ratio 0.76 in Phase III NSCLC trial, data submitted to FDA for pending BLA

  • Updated Phase III HARMONi analysis shows OS hazard ratio 0.76 in both intent-to-treat and Western NSCLC populations, supporting pending BLA.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)